Savara Introduced aPAP ClearPathTM to detect Autoimmune Pulmonary Alveolar Proteinosis
On December 21, 2023, Savara, a clinical stage biopharmaceutical company launched aPAP ClearPathTM, which is used by the physicians to obtain a conclusive diagnosis of Autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare autoimmune lung disease characterized by abnormal accumulation of surfactant sediment in the lung's alveoli or air sacs.
The aPAP ClearPathTM is a quantitative immunoassay test with excellent sensitivity and specificity, which is intended to identify aPAP GM-CSF autoantibodies in human serum.
Savara collaborated with Trillium Hea...
